Neuromodulation Therapy Device for the Treatment of Sleep Apnea
This study is ongoing, but not recruiting participants.
Sponsor:
Mayo Clinic
Collaborator:
Dymedix Corporation
Information provided by (Responsible Party):
John G. Park, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01117064
First received: February 8, 2010
Last updated: July 16, 2012
Last verified: May 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
We are looking to test a novel device in the treatment of Obstructive Sleep Apnea (OSA). Rather than using positive pressure to open the airways, we are testing a device that delivers an auditory tone to affect neuromodulation. We will test its efficacy in treating OSA while minimizing sleep disturbance. As this device is much less cumbersome to wear, we hope this therapy device will also improve compliance with treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Obstructive Sleep Apnea |
Device: Neuromodulation Therapy Device (NMTD) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Neuromodulation Therapy Device for the Treatment of Sleep Apnea |
Resource links provided by NLM:
Further study details as provided by Mayo Clinic:
Primary Outcome Measures:
- We will determine effective device settings on the Neuromodulation Therapy Device (NMTD). [ Time Frame: First year ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- We will compare the modified NMTD's efficacy and tolerability to that of CPAP in treating OSA. [ Time Frame: Second year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 125 |
| Study Start Date: | February 2010 |
| Estimated Study Completion Date: | December 2013 |
| Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: NMTD adjustment testing
We will determine effective NMTD device settings for reducing AHI.
|
Device: Neuromodulation Therapy Device (NMTD)
Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
|
|
Active Comparator: CPAP vs NMTD device
We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices.
|
Device: Neuromodulation Therapy Device (NMTD)
Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
|
|
Active Comparator: NMTD efficacy and tolerability
Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
|
Device: Neuromodulation Therapy Device (NMTD)
Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
|
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects 18 years or older
- Completed a comprehensive Sleep Medicine evaluation and a standard split-night polysomnogram
- Able to give informed consent
- Confirmed diagnosis of OSA
- Positive airway pressure device naive
Exclusion Criteria:
- Unsuccessful CPAP titration
- Inability to detect screening tone in either ear without the use of hearing aid
- Inability to tolerate a 37 dB tone
- Need for nocturnal oxygen or non-invasive positive pressure ventilation due to hypoventilation/hypercapnia
- Predominantly mixed or central apneas or those who develop complex sleep apnea during the PSG
- Neurologic disorders such as seizure disorder or narcolepsy
- Psychiatric disorders currently not under adequate control
- Need for nurse or other's assistance during the night due to problems of nocturnal confusion, delirium, or other conditions that would preclude the subject from wearing the device all night
- Pregnancy (will be tested)
Contacts and Locations More Information
No publications provided
| Responsible Party: | John G. Park, MD, Mayo Clinic |
| ClinicalTrials.gov Identifier: | NCT01117064 History of Changes |
| Other Study ID Numbers: | 09-006804 |
| Study First Received: | February 8, 2010 |
| Last Updated: | July 16, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Mayo Clinic:
|
Sleep Apnea OSA CPAP |
Additional relevant MeSH terms:
|
Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory |
Signs and Symptoms Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013